91 related articles for article (PubMed ID: 20093159)
1. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.
Chae SY; Choi YG; Son S; Jung SY; Lee DS; Lee KC
J Control Release; 2010 May; 144(1):10-6. PubMed ID: 20093159
[TBL] [Abstract][Full Text] [Related]
2. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
Chae SY; Jin CH; Shin JH; Son S; Kim TH; Lee S; Youn YS; Byun Y; Lee MS; Lee KC
J Control Release; 2010 Mar; 142(2):206-13. PubMed ID: 19900495
[TBL] [Abstract][Full Text] [Related]
3. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
Son S; Chae SY; Kim CW; Choi YG; Jung SY; Lee S; Lee KC
J Med Chem; 2009 Nov; 52(21):6889-96. PubMed ID: 19827752
[TBL] [Abstract][Full Text] [Related]
4. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
5. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
Lee J; Lee C; Kim I; Moon HR; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Int J Pharm; 2012 Mar; 424(1-2):50-7. PubMed ID: 22226877
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
10. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.
Fan R; Li X; Gu X; Chan JC; Xu G
Diabetes Obes Metab; 2010 Sep; 12(9):815-24. PubMed ID: 20649634
[TBL] [Abstract][Full Text] [Related]
11. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
Rodriquez de Fonseca F; Navarro M; Alvarez E; Roncero I; Chowen JA; Maestre O; Gómez R; Muñoz RM; Eng J; Blázquez E
Metabolism; 2000 Jun; 49(6):709-17. PubMed ID: 10877194
[TBL] [Abstract][Full Text] [Related]
12. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
14. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
15. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
16. Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.
Arnés L; Moreno P; Nuche-Berenguer B; Valverde I; Villanueva-Peñacarrillo ML
Regul Pept; 2009 Feb; 153(1-3):88-92. PubMed ID: 18804493
[TBL] [Abstract][Full Text] [Related]
17. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
Lee J; Lee C; Kim TH; Chi SC; Moon HR; Oh KT; Lee ES; Lee KC; Youn YS
Regul Pept; 2012 Aug; 177(1-3):68-72. PubMed ID: 22561689
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
Ozyazgan S; Kutluata N; Afşar S; Ozdaş SB; Akkan AG
Pharmacology; 2005 Jun; 74(3):119-26. PubMed ID: 15746570
[TBL] [Abstract][Full Text] [Related]
20. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
